Abstract: Compounds of the formula ##STR1## or the alkyl (1-6 C), alkenyl (1-6 C), or arylalkyl (7-12 C) amides or salts including the cycloamido forms thereof;wherein n is 1 or 2;wherein when n is 1, X is a mono- or disubstituted or unsubstituted hydrocarbyl (1-20 C) moiety optionally containing 1 or 2 nonadjacent heteroatoms (O, S or N), and wherein said substitution is selected from the group consisting of halo, OR, and SR, wherein R is H or lower alkyl (1-4 C); when n is 2, one X is as above defined and the other X is lower alkyl (1-4 C);Y is selected from the group consisting of ##STR2## wherein m is 1 or 2; and AA.sub.C is an amino acid coupled through a peptide bond to the remainder of the compound of formula 1, are useful as affinity ligands, elution reagents, solution inhibitors, diagnostic reagents and therapeutics. These compounds and analogous tripeptide glutathione analogs can be used as members of panels to obtain specific characteristic profiles for various glutathione-S-transferases.

Abstract: A composition of a stabilized fibroblast growth factor (FGF), which contains an aluminum salt of cyclodextrin sulfate to stabilize FGF. FGF can be stabilized by forming a composition of FGF and an aluminum salt of cyclodextrin sulfate, and can be stably prepared into formulations.

Abstract: A substantially purified arabinogalactan, its degradative products and selected modifications thereof have been found to act as carriers for delivering therapeutic agent to cell receptors capable of receptor mediated endocytosis (RME). The arabinogalactan and its degrative products once derivatived are capable of forming a complex between the therapeutic agent and the polysaccharide such that the complex retains the ability to recognize and bind to the RME receptor.

Abstract: The use of hemoglobin-polymer conjugates to enhance antitumor therapy in mammals is disclosed. The methods include administering an effective amount of an antitumor therapy such as radiation in combination with hemoglobin conjugated to a substantially non-antigenic polymer.

Abstract: Prolonged parenteral release of a bioactive somatotropin at desirably effective levels can be achieved using novel compositions in which the somatotropin is present in a biocompatible oil in an unusually high proportion such as at least about 10% by weight. Also disclosed are certain metal-associated somatotropins that are useful for prolonged parenteral release of such somatotropins.

Abstract: A polypeptide derived from leeches of the species Hirudinaria manillensis has the following amino acid sequence: ##STR1## wherein Xaa indicates any amino acid residue; D indicates Cys or Pro; E indicates Glu, Asp or His; F indicates Asp, Lys or Trp; or a pharmaceutically acceptable salt, derivative or bioprecursor thereof. The polypeptide, and fragments thereof, is a specific anti-thrombin useful as a medicament.

Abstract: The present invention relates to peptides and peptide derivatives related to platelet factor 4 which exhibit angiogenic activity, to pharmaceutical compositions comprising said peptides, and to methods for promoting angiogenesis utilizing said peptides. It is based, in part, on the discovery that an octapeptide derived from platelet factor 4 and seven structurally related peptides (depicted in FIG. 1) are capable of inducing an angiogenic response in vivo as measured by neovascularization in rabbit corneal implant assay and by measurement of capillary endothelial cell chemoattraction. The angiogenic peptides of the invention may be particularly useful in promoting wound healing, including incisional healing, bone repair, burn healing, and post-infarction repair in myocardial injury, and in facilitating the assimilation of grafted tissues, particularly in persons suffering from vascular insufficiency, such as diabetic patients.

Abstract: The invention relates to a method of diagnosing and treating individuals with diabetes or at risk to develop diabetes mellitus. In particular, gastric emptying determinations are used to assess risk. Risk or early symptoms associated with subsequent development of diabetes mellitus may be controlled or alleviated by delaying gastric emptying. Delay or inhibition of gastric emptying is sufficient to restore gastric emptying within normal ranges as determined by restoration of typical glucose metabolic parameters such as blood glucose and insulin levels to normal or near normal ranges. The method is also useful in prophylactic treatment of individuals at high risk to develop diabetes mellitus, such as the obese, those with a family history of diabetes and those of particular ethnic and minority groups.

Abstract: Methods for treating cancer are described, including methods for treating colon and pancreatic cancer. Bacterial toxins and portions of bacterial toxins are employed as both diagnostic and therapeutic agents.

Abstract: The present invention provides peptides comprising portions of the amino acid sequence at positions 58-61 of P-selectin. The invention also provides pharmacuetical compositions comprising the peptides of the invention, diagnostic and therapeutic methods utilizing the peptides and pharmaceutical compositions of the invention, and method of preparing the peptides and pharmacuetical compositions.

Abstract: A biologically active amphiphilic peptide which in accordance with an aspect of the present invention, includes one of the following basic structures X.sub.1 through X.sub.7, wherein:X.sub.1 is --[R.sub.1 --R.sub.2 --R.sub.2 --R.sub.3 --R.sub.1 --R.sub.2 --R.sub.2 ]--.sub.nX.sub.2 is --[R.sub.2 --R.sub.2 --R.sub.3 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 ]--.sub.n ;X.sub.3 is --[R.sub.2 --R.sub.3 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 --R.sub.2 ]--.sub.n ;X.sub.4 is --[R.sub.3 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 --R.sub.2 --R.sub.2 ]--.sub.n ;X.sub.5 is --[R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.3 ]--.sub.n ;X.sub.6 is --[R.sub.2 --R.sub.2 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.3 --R.sub.1 ]--.sub.n ; andX.sub.7 is --[R.sub.2 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.3 --R.sub.1 --R.sub.2 ]--.sub.n ;wherein R.sub.1 is a basic hydrophilic amino acid, R.sub.2 is a hydrophobic amino acid, R.sub.3 is a neutral hydrophilic, basic hydrophilic or hydrophobic amino acid and n is from 2 to 5.

Abstract: The radioligands are six amino acid peptides having iodinated tyrosine at amino acid position six, including Ala-pFPhe-hArg-Cha-hArg-Tyr(I)-NH.sub.2, which mimic the activated form of the thrombin receptor protein. Thrombin receptor radioligands of the present invention are useful for screening for thrombin receptor antagonists.

Abstract: Compounds of formula I are described, ##STR1## wherein n is equal to one or two, R.sub.1 stands for hydrogen or an amino protecting group, R.sub.2 represents hydrogen or a carboxyl protecting group and R.sub.3 4-methyltriphenylmethyl, 4,4'-dimethyltriphenylmethyl, 4,4',4"-trimethyltriphenylmethyl. Furthermore described are compounds of formula I which are reactive and suitable for coupling reactions and are derived from I with R.sub.2 =H by activation of the carboxyl group.The compounds mentioned above can be used as starting materials for the synthesis of peptides. They are more suitable than analogous compounds of formula I, wherein R.sub.3 represents hydrogen or a carbamoyl protecting group used hitherto.

Abstract: A peptide ligand analogue of peptide ligands derived from thrombin-cleaved thrombin receptor site on platelets resists inactivation by aminopeptidase M by substituting the .beta.-amino acid isoserine for the N-terminal serine of the peptide ligand.

Abstract: The invention concerns novel renin-inhibitory compounds which contain an amino-substituted heterocycle at the P.sub.2 position. These are useful for treating renin-associated hypertension, congestive heart failure, glaucoma, hyperaldosteronism, and diseases caused by retroviruses including HTLV-I and -III. Processes for preparing the compounds, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, or hyperaldosteronism.

Abstract: A pharmaceutical composition is provided wherein human relaxin is formulated at an acidic pH of about 4 to less than about 7. The composition, useful for effecting parturition and inhibiting premature delivery, includes a buffer capable of maintaining the pH of the composition within a desired range, and may also include an agent to make the composition isotonic, and a stabilizing agent, if necessary. A specific example is human relaxin formulated in a citrate buffer, pH about 5.0, in the presence of sodium chloride, at an ionic strength of about 0.15 .mu..

Abstract: The present invention is directed to a process for treating hypertension in mammals through the administration of an effective amount of a Z-Pro-prolinal (ZPP) composition. In addition, the present invention is also directed to a pharmaceutical composition for treating hypertension in mammals comprised of an active ingredient, Z-Pro-prolinal (ZPP). It has recently been discovered that Z-Pro-prolinal (ZPP) is a useful inhibitor to the biosynthetic formation of Ang(1-7), a previously unknown biologically active hypertensive agent in the reninangiotensin system (RAS). By administering an effective amount of Z-Pro-prolinal (ZPP), Ang-(1-7) formation may be reduced, resulting in a significant decrease in blood pressure without notable changes in heart rate and other circulatory functions.

Abstract: Described is a peptide fragment which comprises the amino acid sequence 95-126 of ANF/CDD 1-126 (gamma-hANaP) and is formed in the kidney. The fragment urodilatin (ANF/CDD 95-126) has the following amino acid sequence: ##STR1## wherein R.sup.1 and R.sup.2 each represent further peptide fragments of ANF/CDD 1-126 (gamma-hANaP). In the amino acid sequence R.sup.1 is Thr-Alo-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser and R.sup.2 is Asn-Ser-Phe-Arg-Tyr. Further described are processes for the preparation and/or recovery of the new peptide fragment and a medicament containing urodilatin (ANF/CDD 95-126 ) as well as medical indications of the medicament.

Abstract: A major heat-stable shrimp allergen is characterized as a 34 kDa protein corresponding to shrimp tropomyosin. Two IgE binding epitopes of this allergen have the sequences FLAEEADRK (SEQ ID NO: 1) and MQQLENDLDQVQESLLK (SEQ ID NO: 2), respectively. Surprisingly, both antigenic and allergenic activities of the allergen were found to be associated with these two peptide fractions. A-a-id antibodies recognized this allergen as well as a homologous 34 kDa allergen from lobster, prawn and crab, indicating that these antibodies recognize major cross-reacting IgE binding epitopes common to crustacea. The two epitopes are useful in the diagnosis and/or treatment of allergies, particularly in the desensitization of individuals that are allergic to shrimp and other crustacea. Variants and subfragments of the two epitopes display allergenicity, as assessed by reaction with allergen-specific IgE obtained from shrimp-sensitive patients.

Abstract: This invention relates to compounds of the formula ##STR1## wherein Q, Z, D, E, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are defined as below, and the pharmaceutically acceptable salts thereof are disclosed. The compounds are useful as antihypertensive agents.